StockData
NervGen Pharma Corp. logo

NervGen Pharma Corp. (NGEN) stock

NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$1.96+0.14 (+7.69%)

Close on Nov 17, 2026Market cap $156.11MP/E –Yield –

NervGen Pharma r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was C$13.47M, down 13.2% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025C$13.47M-13.2%
FY2024Dec 31, 2024C$15.51M–

More NervGen Pharma figures

See a number that looks wrong?